SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials in Australia and New Zealand, with interim results expected by 2026 Joint R&D project between SK and CEPI includes up to ...

Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: ...

Recent positive lab confirmation of Smart mRNA functionality is a tremendous milestone for the Company. This marks a ...

A new LNP-mRNA vaccine significantly boosts immune response and enhances BCG protection against tuberculosis, offering a ...

Allspring Global Investments Holdings LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 12.2% in the fourth quarter, Holdings Channel reports. The firm owned 15,368 shares of ...

Scientists explored the differences in heart inflammation caused by COVID-19, anti-COVID-19 vaccines, and other viral ...

As global capital reassesses the investment value of innovative Chinese companies, the development of innovative vaccines in ...

Clinical studies suggest that the mRNA vaccine could aid in treating pancreatic cancer, one of the most lethal forms of ...

Clinical studies suggest that the mRNA vaccine may play a role in treating pancreatic cancer, identified as one of the most ...

Despite concerns, there was no significant increase in sudden cardiac arrest (SCA) among young athletes during the COVID-19 ...

Memorial Sloan Kettering Cancer Center researchers have found RNA neoantigen vaccines that generate long-lived, functional ...

Vaccines to treat cancers have been around since 2010, the first being approved for prostate cancer, and another in 2015 for ...